A Phase 2, Multicenter, Randomized Study Of Trastuzumab Deruxtecan In Subjects With Her2-Overexpressing Locally Advanced, Unresectable Or Metastatic Colorectal Cancer

  • Body, Amy (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Chief Investigator (CI))

Project: Research

Project Details

Short titleDESTINY-CRC02
StatusActive
Effective start/end date18/06/21 → 17/06/26

Keywords

  • phase 2 study
  • treatment safety
  • treatment efficacy
  • colorectal cancer